P2RY12 and atrial fibrillation: Our preliminary experience in patients with AF managed with carotid artery stenting under heparin anticoagulation and dual antiplatelet therapy who are switched to DOAC and a non-aspirin antiplatelet with a single P2Y12 inhibitor is based on many of the aforementioned concepts: testing the effects of double antiplatelet therapy during the critical time of angioplasty and stent implant followed by rapid conversion to a single P2Y12 antiplatelet regime with proven effectiveness at the time of DOAC restart.